Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®
Working together to bring rapid, automated microbial identification directly from positive blood culture samples
TUCSON, Ariz., Nov. 27, 2023 /PRNewswire/ — Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification. This agreement enables both companies to validate the use of Accelerate Diagnostics’ Arc™ system, an innovative, automated positive blood culture sample preparation platform, with Bruker’s MALDI Biotyper® sirius instruments and Sepsityper® software for subsequent registration in both the US and EMEA markets.
Related news for (BRKR)
- Bruker Appoints Laura Francis to its Board of Directors
- Bruker Announces Quarterly Dividend
- U.S. District Court Awards 10x Genomics Permanent Injunction in Patent Infringement Lawsuit Against Bruker Corporation’s GeoMx Products
- Bruker Announces Quarterly Dividend
- european unified patent court rules in favor of bruker and nanostring, invalidating patent asserted by 10x genomics against nanostring’s cosmx smi products